Trial · NCT04155918
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PD profile of AR882 administered alone or in combination with febuxostat | 22 Days | Profile from serum uric acid concentration over time |
| Primary | PD profile of AR882 administered alone or in combination with allopurinol | 22 Days | Profile from serum uric acid concentration over time. |
| Primary | Serum uric acid (sUA) response rate | 22 Days | sUA response rate to achieve sUA \<6, \<5, \<4, and \<3 mg/dL |
| Secondary | Area under the curve (AUC) for plasma AR882 | 22 Days | Profile from plasma in terms of AUC for AR882 |
| Secondary | Time to maximum plasma concentration (Tmax) for AR882 | 22 Days | Profile from plasma in terms of Tmax for AR882 |
| Secondary | Maximum plasma concentration (Cmax) for AR882 | 22 Days | Profile from plasma in terms of Cmax for AR882 |
| Secondary | Apparent terminal half-life (t1/2) for AR882 | 22 Days | Profile from plasma in terms of t1/2 for AR882 |
| Secondary | Amount excreted (Ae) into urine for AR882 | 22 Days | Profile from urine in terms of Ae for AR882 |
| Secondary | Renal clearance (CLr) for AR882 | 22 Days | Profile from urine in terms of CLr for AR882 |
| Secondary | AUC for plasma for febuxostat | 22 Days | Profile from plasma in terms of AUC for febuxostat |
| Secondary | Tmax for febuxostat | 22 Days | Profile from plasma in terms of Tmax for febuxostat |
| Secondary | Cmax for febuxostat | 22 Days | Profile from plasma in terms of Cmax for febuxostat |
| Secondary | t1/2 for febuxostat | 22 Days | Profile from plasma in terms of t1/2 for febuxostat |
| Secondary | AUC for plasma allopurinol/oxypurinol | 22 Days | Profile from plasma in terms of AUC for allopurinol/oxypurinol |
| Secondary | Tmax for allopurinol/oxypurinol | 22 Days | Profile from plasma in terms of Tmax for allopurinol/oxypurinol |
| Secondary | Cmax for allopurinol/oxypurinol | 22 Days | Profile from plasma in terms of Cmax for allopurinol/oxypurinol |
| Secondary | t1/2 for for allopurinol/oxypurinol | 22 Days | Profile from plasma in terms of t1/2 for allopurinol/oxypurinol |
| Secondary | Ae in urine for allopurinol/oxypurinol | 22 Days | Profile from urine in terms of Ae for allopurinol/oxypurinol |
| Secondary | CLr for allopurinol/oxypurinol | 22 Days | Profile from urine in terms of CLr for allopurinol/oxypurinol |
| Secondary | AUC for plasma for colchicine | 22 Days | Profile from plasma in terms of AUC for colchicine |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04155918/registered